AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39182487 — intervention group
Group type: COMPARATOR
Intervention: IV thrombolysis (IVT) in patients without oral anticoagulation
Number of subjects: 170
Study 39182573 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obesity
Number of subjects: 1370
Study 39182573 — intervention group
Group type: COMPARATOR
Intervention: Patients without obesity
Number of subjects: 1370
Study 39182589 — intervention group
Group type: EXPERIMENTAL
Intervention: RNS60
Number of subjects: 0
Study 39182589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39182617 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet
Number of subjects: 104
Study 39182655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 5 mg/kg IV on Day 1 plus standard of care
Number of subjects: 209
Study 39182655 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV on Day 1 plus standard of care
Number of subjects: 209
Study 39182655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 209
Study 39182655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 39182827 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training
Number of subjects: 96
Study 39182827 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (waitlist control group)
Number of subjects: 96
Study 39182847 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes with meatballs (BFF)
Number of subjects: 26
Study 39182847 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes with plant protein (IMP)
Number of subjects: 26
Study 39182847 — intervention group
Group type: COMPARATOR
Intervention: Rice
Number of subjects: 26
Study 39182847 — intervention group
Group type: EXPERIMENTAL
Intervention: Meatballs
Number of subjects: 26
Study 39182847 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein substitute
Number of subjects: 26
Study 39182902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target home systolic blood pressure <120 mmHg)
Number of subjects: 1675
Study 39182902 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (home systolic blood pressure <135 mmHg)
Number of subjects: 1675
Study 39183039 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat, median dose 3.8 mg/day in Asian patients, 7.3 mg/day in non-Asian patients.
Number of subjects: 210
Study 39183039 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 210
Study 39183095 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based training program (5 sessions, 40 minutes each)
Number of subjects: 92
Study 39183095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 92
Study 39183448 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC training module
Number of subjects: 103
Study 39183448 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIN + CDC training module
Number of subjects: 103
Study 39183572 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous microwave ablation
Number of subjects: 50
Study 39184059 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use cholangioscope for percutaneous transhepatic cholangioscopy
Number of subjects: 0
Study 39184092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 14
Study 39184097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-delivery model (remote mHealth delivery via smartphones with audiovisual content and WhatsApp interactions)
Number of subjects: 1200
Study 39184097 — intervention group
Group type: COMPARATOR
Intervention: In-person group-based delivery model
Number of subjects: 1200
Study 39184944 — intervention group
Group type: EXPERIMENTAL
Intervention: eLIFEwithIBD intervention (ACT and compassion-based online intervention) + medical TAU
Number of subjects: 55
Study 39184944 — intervention group
Group type: COMPARATOR
Intervention: Medical TAU
Number of subjects: 55
Study 39184998 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles (4 injections at 50, 75, and 100 mg/kg) with radiotherapy (RT 60 Gy) and concomitant/adjuvant temozolomide (TMZ)
Number of subjects: 8
Study 39184998 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles (100 mg/kg)
Number of subjects: 8
Study 39184998 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX nanoparticles
Number of subjects: 8
Study 39185280 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Advisory System (SAS) with Analyze Whilst Compressing (AWC) algorithm
Number of subjects: 285
Study 39185280 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock Advisory System (SAS) with AWC algorithm
Number of subjects: 285
Study 39185280 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 285
Study 39185360 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic stimulation (tSMS)
Number of subjects: 40
Study 39185360 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 40
Study 39185368 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced noise environment during induction and emergence
Number of subjects: 64
Study 39185368 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard noise environment)
Number of subjects: 64
Study 39185368 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced noise environment
Number of subjects: 64
Study 39185513 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum neurofilament light (NfL)
Number of subjects: 0
Study 39185513 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NfL
Number of subjects: 0
Study 39185513 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood NfL
Number of subjects: 0
Study 39185526 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECaP intervention (Individualized Coordination and Empowerment for Care Partners of Persons with Dementia)
Number of subjects: 130
Study 39185526 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical support (control)
Number of subjects: 130
Study 39185528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study 39185538 — intervention group
Group type: EXPERIMENTAL
Intervention: MASLIHAT intervention
Number of subjects: 420
Study 39185538 — intervention group
Group type: COMPARATOR
Intervention: Comparison health education training (TANSIHAT)
Number of subjects: 420
Study 39185596 — intervention group
Group type: EXPERIMENTAL
Intervention: SLFN11-positive tumors (e.g., mesotheliomas, clear cell renal cell carcinomas, small cell lung cancers, squamous cell carcinomas of the tonsil and larynx, ovarian serous carcinomas)
Number of subjects: 6658
Study 39185596 — intervention group
Group type: EXPERIMENTAL
Intervention: SLFN11-negative tumors (e.g., hepatocellular, prostatic, colorectal, breast cancers)
Number of subjects: 6658
Study 39185596 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroectodermal and mesenchymal tumors
Number of subjects: 6658
Study 39185596 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of SLFN11 expression
Number of subjects: 6658
Study 39185955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Number of subjects: 88
Study 39185955 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 88
Study 39185955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 39186143 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on dupilumab therapy
Number of subjects: 0
Study 39186143 — intervention group
Group type: COMPARATOR
Intervention: Background therapy alone
Number of subjects: 0
Study 39186271 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for 9 weeks
Number of subjects: 2174
Study 39186271 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab for 1 year
Number of subjects: 2174
Study 39186268 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy
Number of subjects: 415
Study 39186268 — intervention group
Group type: COMPARATOR
Intervention: Patient navigation
Number of subjects: 415
Study 39186273 — intervention group
Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing (ITH)
Number of subjects: 101
Study 39186273 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 101
Study 39186315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 14
Study 39186315 — intervention group
Group type: COMPARATOR
Intervention: Any other therapy
Number of subjects: 14
Study 39186326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing implant surgery using the MONO procedure
Number of subjects: 51
Study 39186356 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal corset
Number of subjects: 100
Study 39186356 — intervention group
Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 100
Study 39186380 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy
Number of subjects: 0
Study 39186385 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39186458 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Blood Flow Restriction Training
Number of subjects: 0
Study 39186458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39186573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60
Study 39186573 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60
Study 39186573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 60
Study 39186573 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 39186588 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (MM e-coach)
Number of subjects: 150
Study 39186588 — intervention group
Group type: COMPARATOR
Intervention: Standard MM care
Number of subjects: 150
Study 39186707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of 21-day cycles
Number of subjects: 38
Study 39186768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (SYV): The Voice of Youth intervention, consisting of a 10-session group-based intervention and two individual sessions.
Number of subjects: 100
Study 39186768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauti ya Vijana (SYV) intervention
Number of subjects: 100
Study 39186770 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgrants with peer mentoring
Number of subjects: 360
Study 39186770 — intervention group
Group type: COMPARATOR
Intervention: Microgrants without peer mentoring
Number of subjects: 360
Study 39186770 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (single microgrant plus monthly financial literacy education)
Number of subjects: 360
Study 39186770 — intervention group
Group type: COMPARATOR
Intervention: Extended microgrants (enhanced usual care plus monthly microgrants)
Number of subjects: 360
Study 39186774 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated proactive supportive care pathways
Number of subjects: 12
Study 39186785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor yoga program
Number of subjects: 240
Study 39186785 — intervention group
Group type: COMPARATOR
Intervention: Physical conditioning program
Number of subjects: 240
Study 39186921 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg
Number of subjects: 253
Study 39186921 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg
Number of subjects: 253
Study 39186921 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine
Number of subjects: 253
Study 39186921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 39186921 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 253
Study 39186971 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) psychotherapy
Number of subjects: 46
Study 39186971 — intervention group
Group type: COMPARATOR
Intervention: Relapse Prevention (RP) psychotherapy
Number of subjects: 46
Study 39186971 — intervention group
Group type: EXPERIMENTAL
Intervention: Geospatial analyses
Number of subjects: 46
Study 39187200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d for bipolar I mania
Number of subjects: 0
Study 39187200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d or 3 mg/d for bipolar I depression
Number of subjects: 0
Study 39187200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39187267 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 0
Study 39187267 — intervention group
Group type: COMPARATOR
Intervention: 5-Time Sit-to-Stand (5STS) test
Number of subjects: 0
Study 39187267 — intervention group
Group type: COMPARATOR
Intervention: Grip strength
Number of subjects: 0
Study 39187267 — intervention group
Group type: COMPARATOR
Intervention: Trail Making Test (TMT)
Number of subjects: 0
Study 39187267 — intervention group
Group type: COMPARATOR
Intervention: Visuospatial Memory Test (VSMT)
Number of subjects: 0
Study 39187267 — intervention group
Group type: COMPARATOR
Intervention: Tap Fast
Number of subjects: 0
Study 39187267 — intervention group
Group type: EXPERIMENTAL
Intervention: TMT-A
Number of subjects: 0
Study 39187267 — intervention group
Group type: EXPERIMENTAL
Intervention: TMT-B
Number of subjects: 0
Study 39187267 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit Span Test (DST)
Number of subjects: 0
Study 39187267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap Fast score
Number of subjects: 0
Study 39187401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg once daily for up to 1 year
Number of subjects: 0
Study 39187401 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 39187558 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with pembrolizumab
Number of subjects: 837
Study 39187558 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (CRT) with pembrolizumab
Number of subjects: 837
Study 39187558 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (no RT) with pembrolizumab
Number of subjects: 837
Study 39187558 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 837
Study 39187558 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 837
Study 39187558 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (no RT)
Number of subjects: 837
Study 39187595 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TIGIT antibody
Number of subjects: 12
Study 39187595 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-LAG3 antibody
Number of subjects: 12
Study 39187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine with medication overuse (CM-MO)
Number of subjects: 128
Study 39187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 128
Study 39187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine participants (both EM and CM-MO)
Number of subjects: 128
Study 39187749 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-155
Number of subjects: 128
Study 39187749 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 128
Study 39187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjacent periodontal crevicular fluid (ToCF)
Number of subjects: 0
Study 39187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Crevicular fluid from transepithelial abutment (TACF)
Number of subjects: 0
Study 39187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial abutment (TA)
Number of subjects: 0
Study 39187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentially abundant taxa
Number of subjects: 0
Study 39187802 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential network properties and association patterns
Number of subjects: 0
Study 39187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education (Zoom)
Number of subjects: 20
Study 39187817 — intervention group
Group type: COMPARATOR
Intervention: Onsite education (The Parker Institute, Denmark)
Number of subjects: 20
Study 39187877 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 72
Study 39188412 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance chiropractic therapy (BCT) for 20 days
Number of subjects: 240
Study 39188412 — intervention group
Group type: COMPARATOR
Intervention: Traction therapy (TT)
Number of subjects: 240
Study 39188413 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal school-based prevention programs
Number of subjects: 0
Study 39188413 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39188767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-rituximab (TAC-RTX)
Number of subjects: 34
Study 39188767 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids-cyclophosphamide (GC-CYC)
Number of subjects: 34
Study 39188767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and urinary cytokines
Number of subjects: 34
Study 39188767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine clusters
Number of subjects: 34
Study 39188767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and urinary growth differentiation factor 15 (GDF15)
Number of subjects: 34
Study 39188767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma tumour necrosis factor α and urinary TNF-like weak inducer of apoptosis
Number of subjects: 34
Study 39188767 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urinary CXCL13 concentration
Number of subjects: 34
Study 39188940 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic group treatment protocol administered in a blended format
Number of subjects: 0
Study 39188940 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face treatment
Number of subjects: 0
Study 39188943 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 300 mg
Number of subjects: 18
Study 39188943 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-437c 400 mg
Number of subjects: 18
Study 39188943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 39188996 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography after intravenous administration of 296 MBq
Number of subjects: 366
Study 39188996 — intervention group
Group type: COMPARATOR
Intervention: Positron emission tomography/computed tomography
Number of subjects: 366
Study 39188996 — intervention group
Group type: EXPERIMENTAL
Intervention: SoT-verification predominantly with conventional imaging
Number of subjects: 366
Study 39189160 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (G_TECCU)
Number of subjects: 150
Study 39189160 — intervention group
Group type: COMPARATOR
Intervention: Standard care (G_Control)
Number of subjects: 150
Study 39189473 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal Atrial Fibrillation (PAF)
Number of subjects: 1369
Study 39189473 — intervention group
Group type: COMPARATOR
Intervention: Persistent Atrial Fibrillation (Persistent AF)
Number of subjects: 1369
Study 39189517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0
Study 39189547 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 150
Study 39189547 — intervention group
Group type: COMPARATOR
Intervention: Observation without intervention (OBS)
Number of subjects: 150
Study 39189858 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg orally twice daily for days 1 to 112
Number of subjects: 140
Study 39189858 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without NAC
Number of subjects: 140
Study 39190027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 26
Study 39190441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach (MC) mobile app
Number of subjects: 0
Study 39190441 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39190445 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic attachment controlled for avoidant attachment characteristics
Number of subjects: 330
Study 39190445 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing engagement in therapy
Number of subjects: 330
Study 39190445 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic attachment controlled for anxious attachment characteristics
Number of subjects: 330
Study 39190534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA4) for CD8-low patients (CD8 <15%)
Number of subjects: 79
Study 39190534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy for CD8-high patients (CD8 ≥15%)
Number of subjects: 79
Study 39190595 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVI
Number of subjects: 24305
Study 39190675 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parent training program (Attend Behavior) for 12 weeks
Number of subjects: 0
Study 39190675 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline survey
Number of subjects: 0
Study 39190675 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention survey
Number of subjects: 0
Study 39190675 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 interview with study team member
Number of subjects: 0
Study 39190675 — intervention group
Group type: EXPERIMENTAL
Intervention: Study retention and participant app usage data
Number of subjects: 0
Study 39190826 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 158
Study 39190826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 158
Study 39190853 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Number of subjects: 1072
Study 39190853 — intervention group
Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 1072